STOCK TITAN

Vanguard (DGX) amends 13G, reports 0 shares after Jan 12, 2026 realignment

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group amended its Schedule 13G for Quest Diagnostics Inc. The filing states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Quest Diagnostics common stock and 0% of the class as of 03/13/2026. The amendment explains that certain subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard disaggregated holdings and reports zero beneficial ownership after internal realignment.

The filing documents an internal realignment effective January 12, 2026 and relies on SEC Release No. 34-39538 for disaggregated reporting. It explicitly lists 0 shares and 0% beneficial ownership of Quest Diagnostics common stock in the amendment.

This is an administrative ownership disclosure reflecting reporting structure changes rather than a purchase or sale. Subsequent filings from Vanguard or the named subsidiaries may show separate beneficial positions for related entities.






74834L100

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What does Vanguard's Schedule 13G/A for Quest Diagnostics (DGX) state?

It states 0 shares beneficially owned and 0% of the class as reported in the amendment. The filing cites an internal realignment and reliance on SEC Release No. 34-39538 for disaggregated reporting following January 12, 2026.

Why did The Vanguard Group change its reporting for DGX?

Because of an internal realignment within Vanguard effective January 12, 2026, certain subsidiaries will report beneficial ownership separately. The amendment references SEC Release No. 34-39538 as the basis for disaggregation.

Does the amendment show any Vanguard subsidiary owning Quest Diagnostics shares?

The amendment itself reports 0 shares for The Vanguard Group as amended. It explains subsidiaries will report separately; specific subsidiary holdings are not included in this amendment.

Who signed the Schedule 13G/A amendment for Vanguard and when?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date of 03/27/2026. The document lists Vanguard's Malvern, PA address.
Quest Diagnostics Inc

NYSE:DGX

View DGX Stock Overview

DGX Rankings

DGX Latest News

DGX Latest SEC Filings

DGX Stock Data

21.77B
109.35M
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS